Diligence memo · auto-generated · as of July 2, 2026
Split Biosciences, Inc.
Split Biosciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Split Biosciences, Inc. operates in Biotech / Pharma, based in SEATTLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Split Biosciences, Inc. has raised $1.8M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.2M on 2018-09-28.
Most recent recorded round closed around 2019-08-27.
Valuation (modeled)modeled
Provath models Split Biosciences, Inc. at approximately $23M (range $413K–$181M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.68× the median modeled value of Seed Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era. Within the normal band (68% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 6.8 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 35% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 46% of those peers.
Closest niche peers: rMark Bio, Inc., Massive Bio, Inc., Light Bio, Inc., Agronomed Pharmaceuticals LLC, Cellix Biosciences, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.